Both Izervay and Syfovre are eye injections used to treat geographic atrophy caused by AMD. They work similarly to one another to manage this condition. Because of this, they can cause some ...

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

While Syfovre targets complement C3, Izervay – formerly known as Zimura – is a C5 inhibitor. In a bid to differentiate the new product from its rival, Astellas said that Izervay is the only GA ...

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

“Note there is a factor of two favoring Astellas’s chosen metric, given Izervay is monthly vs Syfovre’s majority use on the ...

These injections deliver medication such as the new geographic atrophy drugs Syfovre (pegcetacoplan) and Izervay ...

Both Syfovre and Izervay must be injected directly into the eye once per month, or every other month, on an ongoing basis. They prevent damage to retinal cells by calming the immune response and ...

Analyst Derek Archila of Wells Fargo assigned a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...

For wet AMD, there are several anti-VEGF medications like Avastin, Lucentis and Eylea that can stop vision loss and may even ...